Skip to main content
Clinical Trials/NCT03000764
NCT03000764
Completed
Not Applicable

Study of RNA and Heat Shock Protein (HSP) Derived Biomarkers in Radiation-induced Fibrosis in Patients Treated for Breast Cancer.

Institut de Cancérologie de Lorraine1 site in 1 country20 target enrollmentMay 10, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Carcinoma
Sponsor
Institut de Cancérologie de Lorraine
Enrollment
20
Locations
1
Primary Endpoint
Global mRNA alternative splicing and expression of non-coding RNAs profiles in healthy dermal fibroblasts
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to seeking a molecular signature of pathological radiation induced fibrosis based on the response of skin fibroblasts after irradiation, comparing two groups of patients distinguished by their individual radiosensitivity. The signature will integrate recent insights in terms of alternative splicing of mRNAs and level of expression of non-coding RNAs, particularly long non-coding RNAs, snRNAs, snoRNAs and microRNAs. In each group each expression patterns of candidate HSP proteins potentially predictive of pathological radiation induced fibrosis (HSP27, HSP70, αβ crystalline) in the serum and on cell culture will be characterized.

Registry
clinicaltrials.gov
Start Date
May 10, 2017
End Date
April 25, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Institut de Cancérologie de Lorraine
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • age ≥ 18 and \<70 years old
  • non metastatic disease
  • ECOG performance status 0 or 1
  • chest size ≤ 110 cm et bra size \<D
  • absence of reconstructive breast surgery
  • patient able to undergo blood samples (haematological conditions allowing blood sample)
  • non-evolving carcinological disease
  • absence of systemic inflammatory disease (other than scleroderma) or diabetes
  • no inflammatory ou infectious flare on biopsy site at the time of inclusion
  • invasive or in situ breast carcinoma

Exclusion Criteria

  • age \<18 or \> 70 years old
  • evolutive cancer / metastatic disease
  • chest size \> 110 cm et bra size ≥ D
  • previous reconstructive breast surgery
  • ECOG performance status \> 1
  • systemic inflammatory disease or diabetes
  • inflammatory ou infectious flare on biopsy site at the time of inclusion, very significant ulceration in the treated breast
  • anemic patients
  • use of oral anticoagulants
  • pregnant or likely to be in 6 months

Outcomes

Primary Outcomes

Global mRNA alternative splicing and expression of non-coding RNAs profiles in healthy dermal fibroblasts

Time Frame: 6 months

frequency of inclusion of individual exons within the set of mRNA isoforms (overall splicing profile) and variation in expression of non-coding RNAs

Secondary Outcomes

  • Transcriptomic signature of pathological induced fibrosis when comparing the primary outcome between the two populations on cultured fibroblasts(6 months)
  • Transcriptomic signature of pathological induced fibrosis when comparing the primary outcome between the two populations on serum(6 months)
  • Individual radiosensitivity on healthy dermal fibroblasts(6 months)
  • Comparison of the overall mRNA splicing and non-coding RNA expression profiles between non irradiated and irradiated dermal fibroblasts in the same individual(6 months)
  • Changes in cellular distribution of the main non-coding RNAs whose expression varies significantly within the pre-identified signature between the 2 groups of patients(6 months)
  • seric HSP proteins potentially predictive of pathological induced fibrosis(6 months)
  • Cellular distribution of specific HSP on fibroblast culture in each group of patients(6 months)
  • Potential interactions between DNA damage response proteins and candidate HSP(6 months)

Study Sites (1)

Loading locations...

Similar Trials